# Preoperative PRRT Versus Surgical Cytoreduction in Metastatic Pancreatic Neuroendocrine Tumors to the Liver

> **NCT05610826** · PHASE1,PHASE2 · WITHDRAWN · sponsor: **University of Chicago**

## Conditions studied

- Pancreatic Neuroendocrine Tumor
- Pancreas Cancer

## Interventions

- **PROCEDURE:** cytoreductive surgery
- **DRUG:** Lutathera - a small molecule used in Peptide Receptor Radionuclide Therapy (PRRT)
- **PROCEDURE:** Peptide receptor radionuclide therapy (PRRT)

## Key facts

- **NCT ID:** NCT05610826
- **Lead sponsor:** University of Chicago
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2023-03-07
- **Primary completion:** 2024-09-11
- **Final completion:** 2024-09-11
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** 0 enrollment
- **Last updated:** 2024-10-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05610826

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05610826, "Preoperative PRRT Versus Surgical Cytoreduction in Metastatic Pancreatic Neuroendocrine Tumors to the Liver". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05610826. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*